392 material Form 8-K filings that 341 companies we cover made with the SEC in July 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Wyndham Hotels & Resorts reported second-quarter 2024 results with diluted EPS of $1.07, up from $0.82 a year earlier, and net income of $86 million, up from $70 million. The company raised its full-year adjusted diluted EPS outlook to $4.20 to $4.32 while lowering its fee-related and other revenues outlook to $1.41 to $1.43 billion and its global RevPAR outlook to approximately flat, which the company attributed to a more moderated RevPAR acceleration than previously anticipated.
Q2 2024 diluted EPS was $1.07 versus $0.82 in Q2 2023; net income was $86 million versus $70 million
Fee-related and other revenues were $366 million versus $358 million; global RevPAR rose 2% in constant currency
Full-year 2024 adjusted diluted EPS outlook raised to $4.20 to $4.32 from $4.18 to $4.30
Full-year fee-related and other revenues outlook cut to $1.41 to $1.43 billion from $1.43 to $1.46 billion; global RevPAR outlook changed to approximately flat from 2% to 3% growth
Edwards reported second-quarter sales of $1,385.9 million, up 7%, and GAAP diluted EPS of $0.61 versus $0.50 a year earlier. It cut full-year TAVR sales growth guidance to 5 to 7% from 8 to 10%, raised TMTT guidance to the higher end of $320 to $340 million, and agreed to buy JenaValve and exercise its option to buy Endotronix for about $1.2 billion in cash plus up to $445 million in milestone payments.
Q2 net sales of $1,385.9 million, up 7% from $1,295.5 million; TMTT sales rose 75% to $83 million
Full-year 2024 TAVR sales growth guidance lowered to 5 to 7% from 8 to 10%; total Edwards sales growth guidance kept at 8 to 10%
Acquisitions of JenaValve and Endotronix carry about $1.2 billion upfront cash plus up to $445 million on milestones, subject to closing conditions
Critical Care sale for $4.2 billion remains on track to close in late Q3 2024
Plexus reported fiscal third-quarter 2024 revenue of $961 million, down from $1.02 billion a year earlier, while GAAP diluted EPS rose to $0.91 from $0.56. The company guided fiscal fourth-quarter revenue to $990 million to $1.03 billion and GAAP diluted EPS to $1.14 to $1.29, and said it expects free cash flow of more than $150 million for fiscal 2024.
Q3 revenue was $961 million, versus $1.02 billion in the year-earlier quarter and $967 million in the prior quarter.
Q3 GAAP diluted EPS was $0.91, versus $0.56 a year earlier; non-GAAP diluted EPS was $1.45, versus $1.46.
Q4 guidance: revenue of $990 million to $1.03 billion and GAAP diluted EPS of $1.14 to $1.29.
Free cash flow was $114 million in Q3, and the company repurchased $18.6 million of shares with $19.5 million left on its $50.0 million authorization.
Annaly Capital Management reported a GAAP net loss of $0.09 per average common share for the quarter ended June 30, 2024, compared with GAAP net income of $0.85 per share in the prior quarter. Earnings available for distribution rose to $0.68 per share from $0.64 in the first quarter, but book value per common share fell to $19.25 from $19.73, and the company declared a $0.65 quarterly dividend.
GAAP net loss of $0.09 per share for Q2 2024, versus $0.85 in Q1 2024 and $0.27 in Q2 2023
Earnings available for distribution of $0.68 per share, up from $0.64 in Q1 2024 but down from $0.72 in Q2 2023
Book value per common share of $19.25 at June 30, 2024, down from $19.73 at March 31, 2024
GAAP leverage rose to 7.1x from 6.7x in the prior quarter; quarterly common dividend of $0.65 per share declared
ServiceNow reported second-quarter 2024 total revenues of $2,627 million, up 22% year over year, and raised its 2024 subscription revenue guidance to $10,575 million to $10,585 million. The same day, President and Chief Operating Officer CJ Desai agreed to resign effective immediately after an internal investigation found that he and another individual violated company policy over a 2023 hire tied to a U.S. Army government contract, and the Department of Justice has opened its own investigation.
Total revenues $2,627 million, up 22% year over year; subscription revenues $2,542 million, up 23%.
GAAP net income $262 million, or $1.26 per diluted share, versus $1,044 million in Q2 2023.
Full-year 2024 subscription revenue guidance set at $10,575 million to $10,585 million.
CJ Desai resigned effective July 24, 2024; Chris Bedi named interim Chief Product Officer.
Pathward Financial reported results for the three months ended June 30, 2024. Net income was $41.8 million, or $1.66 per share, down from $45.1 million, or $1.68 per share, a year earlier, even though total revenue rose 7% to $176.7 million. For shareholders, higher revenue was offset by slightly lower profit and higher noninterest expense.
Net income $41.8 million, or $1.66 per share, for the quarter ended June 30, 2024, versus $45.1 million, or $1.68 per share, a year earlier
Total revenue $176.7 million, up $11.5 million or 7%, driven by higher net interest income
Net interest margin rose to 6.56% from 6.18%; noninterest expense rose 8% to $123.7 million
Nonperforming loans and leases were $44.6 million, or 0.96% of gross loans, at June 30, 2024, up from $34.4 million at March 31, 2024
Align Technology reported second-quarter 2024 revenue of $1,028.5 million, up 2.6% from a year earlier, while GAAP net income fell 13.6% to $96.6 million, or $1.28 per diluted share. The company also revised its fiscal 2024 revenue outlook to 4% to 6% growth, citing a delayed launch of the iTero Lumina with restorative capabilities to the first quarter of 2025, which affects expectations for shareholders.
Q2 2024 revenue was $1,028.5 million, up 2.6% year-over-year; GAAP diluted EPS was $1.28 versus $1.46 a year earlier.
Non-GAAP diluted EPS was $2.41, compared with $2.22 in Q2 2023.
Q3 2024 worldwide revenue is expected in the range of $980 million to $1,000 million; fiscal 2024 revenue growth is expected to be 4% to 6%.
Align agreed in principle to settle legal matters for $31.1 million, primarily related to the Misty Snow Antitrust Class Action.
PROG Holdings reported second quarter 2024 revenue of $592.2 million, flat with the prior year, and diluted EPS of $0.77 versus $0.79 a year earlier. The company raised its full-year 2024 revenue and diluted EPS outlook, citing 7.9% year-over-year growth in Progressive Leasing GMV, though net earnings declined.
Q2 net earnings were $33.8 million versus $37.2 million; diluted EPS was $0.77 versus $0.79.
Progressive Leasing GMV rose 7.9% to $454.5 million year over year.
2024 revenue outlook raised to $2.40 billion-$2.45 billion from $2.285 billion-$2.36 billion; diluted EPS outlook raised to $2.52-$2.68 from $2.18-$2.43.
Third quarter 2024 diluted EPS outlook is $0.61-$0.71.
Silicon Labs reported second-quarter 2024 results for the quarter ended June 29, 2024, with revenue of $145 million, down from $245 million a year earlier. The company posted a GAAP operating loss of $48 million and a GAAP diluted loss of $(2.56) per share, compared with diluted earnings of $0.33 per share a year earlier. It expects third-quarter revenue of $160 million to $170 million, which would be above the second-quarter level.
Q2 2024 revenue was $145 million versus $245 million in Q2 2023; Industrial & Commercial revenue was $88 million and Home & Life revenue was $57 million.
GAAP operating loss was $48 million and GAAP diluted loss per share was $(2.56), versus diluted earnings of $0.33 per share in Q2 2023.
Non-GAAP diluted loss per share was $(0.56) for the quarter.
Third-quarter 2024 outlook: revenue of $160 million to $170 million; GAAP diluted loss per share of $(0.95) to $(1.25); non-GAAP diluted loss per share of $(0.10) to $(0.30).
Healthcare Services Group reported a second-quarter net loss of $1.8 million, or $0.02 per diluted share, compared with net income of $8.3 million a year earlier, even though revenue rose to $426.3 million. The company said the loss reflects client restructuring charges, including those tied to the LaVie Care Centers Chapter 11 filing. The company raised its third- and fourth-quarter revenue estimates and reaffirmed its 2024 adjusted cash flow forecast of $40.0 million to $55.0 million.
Q2 2024 revenue was $426.3 million, up from $418.9 million in Q2 2023 and in line with the company's expectation of $420.0 million to $430.0 million.
Net loss of $1.8 million, or $0.02 per diluted share, versus net income of $8.3 million, or $0.11 per diluted share, in Q2 2023; results include a $0.22 per share impact from client restructuring bad debt expense.
Q3 2024 revenue estimate raised to $425.0 million to $435.0 million; Q4 2024 estimate raised to $430.0 million to $440.0 million.
2024 adjusted cash flow from operations forecast of $40.0 million to $55.0 million reaffirmed; Q2 adjusted cash flow used in operations was $2.4 million.
Blackstone Mortgage Trust reported a second quarter 2024 net loss attributable to the company of $61 million, or ($0.35) per share, compared with net income of $101.7 million in the same quarter of 2023. The company also declared a third quarter dividend of $0.47 per share, down from the $0.62 per share paid for the second quarter, and authorized a share repurchase program of up to $150.0 million.
Q2 2024 net loss attributable to the company of $61 million, or ($0.35) per share, versus net income of $101.7 million in Q2 2023
Distributable EPS of $0.49 for Q2 2024, up from $0.33 in Q1 2024; Distributable EPS prior to charge-offs was $0.56
Q3 2024 dividend of $0.47 per share, payable October 15, 2024, to stockholders of record as of September 30, 2024
Board authorized a share repurchase program of up to $150.0 million of class A common stock
Otis reported second quarter 2024 net sales of $3.6 billion, down 3.2% from a year earlier, while GAAP EPS rose 13.3% to $1.02 and adjusted EPS rose 15.2% to $1.06. The company raised its full-year adjusted EPS outlook to $3.85 to $3.90, up 9% to 10%, though organic sales for the full year are now expected to rise only 1% to 3%.
Q2 2024 net sales were $3.6 billion, down 3.2%; organic sales fell 1.2%, with New Equipment sales down 11.4% and Service sales up 3.0%.
GAAP EPS was $1.02 (up 13.3%) and adjusted EPS was $1.06 (up 15.2%); GAAP operating profit was $570 million.
Full-year 2024 outlook: net sales of $14.3 billion to $14.5 billion and adjusted EPS of $3.85 to $3.90.
Otis repurchased $300 million of shares in the second quarter and $600 million in the first half of 2024.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.